- First ready-to-use subcutaneous formulation of bortezomib now available
- Marks Amneal’s fourth 505(b)(2) injectable product launch in the last year
Amneal Pharmaceuticals Inc., a global biopharmaceutical company, and Shilpa Medicare Limited announced the U.S. launch of Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous or IV administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration.
Boruzu